Summary of Significant Accounting Policies - Revenue from contract with customers (Details) - GlaxoSmithKline Intellectual Property Development Ltd - Collaboration and License Agreement |
12 Months Ended |
|---|---|
|
Dec. 31, 2019
USD ($)
contract
| |
| Collaboration and License Agreement | |
| Number of contracts with customers | contract | 1 |
| Amount of development milestone achieved | $ 3,200,000 |
| Estimate of variable consideration | $ 0 |
| X | ||||||||||
- Definition Represents cash received upon achievement of development milestones. No definition available.
|
| X | ||||||||||
- Definition Represents the variable consideration entitled upon achievement of development milestones. No definition available.
|
| X | ||||||||||
- Definition Represents the total number of contracts with customers. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|